JP2000507939A5 - - Google Patents

Download PDF

Info

Publication number
JP2000507939A5
JP2000507939A5 JP1997533791A JP53379197A JP2000507939A5 JP 2000507939 A5 JP2000507939 A5 JP 2000507939A5 JP 1997533791 A JP1997533791 A JP 1997533791A JP 53379197 A JP53379197 A JP 53379197A JP 2000507939 A5 JP2000507939 A5 JP 2000507939A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP1997533791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000507939A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/005071 external-priority patent/WO1997034618A1/en
Publication of JP2000507939A publication Critical patent/JP2000507939A/ja
Publication of JP2000507939A5 publication Critical patent/JP2000507939A5/ja
Withdrawn legal-status Critical Current

Links

JP9533791A 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与 Withdrawn JP2000507939A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620,444 1996-03-22
PCT/US1997/005071 WO1997034618A1 (en) 1996-03-22 1997-03-21 Administration of polypeptide growth factors following central nervous system ischemia or trauma

Publications (2)

Publication Number Publication Date
JP2000507939A JP2000507939A (ja) 2000-06-27
JP2000507939A5 true JP2000507939A5 (enExample) 2004-12-02

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法
JP9533791A Withdrawn JP2000507939A (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法

Country Status (11)

Country Link
US (4) US6214796B1 (enExample)
EP (3) EP0904093A4 (enExample)
JP (2) JP4847634B2 (enExample)
KR (1) KR20000064752A (enExample)
CN (1) CN1181885C (enExample)
AT (2) ATE244574T1 (enExample)
AU (2) AU725341B2 (enExample)
CA (2) CA2249368A1 (enExample)
DE (2) DE69723429T3 (enExample)
ES (1) ES2201287T5 (enExample)
WO (2) WO1997034626A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
KR100227406B1 (ko) 1993-05-12 1999-12-01 브루스 엠. 에이센 Bmp-11 조성물
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
DK0980252T3 (da) * 1997-05-05 2005-01-31 Curis Inc Terapier til akut nyresvigt
WO1998054572A1 (en) * 1997-05-30 1998-12-03 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
EP1037910A2 (en) * 1997-12-04 2000-09-27 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
EP1210106A2 (en) * 1999-08-18 2002-06-05 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US7060676B2 (en) * 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
CA2411666A1 (en) * 2000-06-01 2001-12-06 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
CN1520312A (zh) * 2001-06-01 2004-08-11 �Ƹ��� T细胞诱导的组织修复和再生
CA2449008A1 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
WO2004047871A2 (en) 2002-11-26 2004-06-10 Nobex Corporation Modified naturetic compounds, conjugates, and uses thereof
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
US20040224402A1 (en) 2003-05-08 2004-11-11 Xcyte Therapies, Inc. Generation and isolation of antigen-specific T cells
EP1773871B1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US20080108547A1 (en) * 2004-07-20 2008-05-08 Taylor Ii Larry Edmund Protease Inhibitor
EP1782821A4 (en) * 2004-07-29 2009-11-11 Anges Mg Inc MEDICAMENT AND METHOD FOR IMPROVING BRAIN FUNCTION
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
PL2497780T3 (pl) 2005-09-20 2015-09-30 Thrasos Innovation Inc Związki pokrewne TDF oraz ich analogi
EP2564864B8 (en) 2005-11-12 2015-05-13 The Board of Trustees of The Leland Stanford Junior University FGF2-related methods for diagnosing and treating depression
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
DK2121142T3 (da) * 2007-01-25 2013-07-29 Bioph Biotech Entw Pharm Gmbh Anvendelse af GDF-5 til forbedring eller vedligeholdelse af hudens udseende
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
US8058237B2 (en) 2007-08-07 2011-11-15 Advanced Technologies & Regenerative Medicine, LLC Stable composition of GDF-5 and method of storage
WO2009129101A1 (en) * 2008-04-14 2009-10-22 Advanced Technologies And Regenerative Medicine, Llc Liquid buffered gdf-5 formulations
EP2396026A2 (en) * 2009-02-12 2011-12-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including tgf- superfamily members
US20100204123A1 (en) * 2009-02-12 2010-08-12 Mary Elizabeth Pecquet Goad Peripheral Administration of Proteins Including TGF-beta Superfamily Members for Treatment of Systemic Disorders and Disease
CN102369212B (zh) 2009-03-12 2015-12-16 哈瑟投资公司 具有降低的bmp拮抗剂敏感性的骨形成蛋白2(bmp2)变体
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
US20110224410A1 (en) 2009-09-17 2011-09-15 Hile David Buffers for Controlling the pH of Bone Morphogenetic Proteins
CN102822197A (zh) 2009-12-22 2012-12-12 史赛克公司 具有降低的免疫原性的bmp-7变体
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
BR112013003587B1 (pt) 2010-08-20 2022-11-08 Wyeth Llc Proteínas osteogênicas projetadas, seus usos, seu método de produção e molécula de ácido nucleico isolada
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CA2829006A1 (en) * 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
CN106478776A (zh) * 2011-07-19 2017-03-08 特拉索斯创新公司 抗纤维化肽及其在用于治疗以纤维化为特征的疾病和病症的方法中的用途
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
SI2981822T1 (sl) 2013-05-06 2021-08-31 Scholar Rock, Inc. Sestavki in postopki za modulacijo rastnega dejavnika
EP3007719B1 (en) * 2013-06-11 2021-03-17 President and Fellows of Harvard College Methods and compositions for increasing neurogenesis and angiogenesis
EP4406585A3 (en) 2015-02-13 2024-10-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
WO2018035377A1 (en) 2016-08-17 2018-02-22 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
US20200009226A1 (en) * 2018-07-03 2020-01-09 Cardiovascular Biotherapeutics, Inc. Compositions and Methods for Treating Stroke
CN115190886A (zh) * 2020-02-20 2022-10-14 马斯特里赫特大学 循环bmp10（骨形态发生蛋白10）的检测方法
AU2021273813A1 (en) * 2020-05-19 2023-02-02 Elevian, Inc. Methods and compositions for treating stroke
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
DE3382562D1 (de) 1982-09-24 1992-06-25 Us Health Wiederherstellung von gewebe bei tieren.
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
JPH03505669A (ja) 1988-07-08 1991-12-12 ユニバーシテイ・カレツジ・ロンドン バイオアツセイにおける改良
WO1990000900A1 (en) 1988-07-20 1990-02-08 Amgen Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
EP0448704B1 (en) 1989-10-17 1998-06-17 Stryker Corporation Osteogenic devices
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
AU666291B2 (en) 1990-06-15 1996-02-08 Carnegie Institution Of Washington Gdf-1
ATE253589T1 (de) 1990-09-26 2003-11-15 Inst Genetics Llc Bmp-5-derivate
JPH07500487A (ja) 1990-10-18 1995-01-19 ストライカー コーポレイション 骨形成ペプチド
WO1992008480A1 (en) 1990-11-16 1992-05-29 Celtrix Pharmaceuticals, Inc. A β-TYPE TRANSFORMING GROWTH FACTOR
ATE212554T1 (de) 1990-11-27 2002-02-15 American Nat Red Cross Gewebeabdeckung und wachstumsfaktor enthaltende verbindungen zur förderung beschleunigter wundheilung
EP0513334A4 (en) 1990-11-30 1993-08-04 Celtrix Laboratories, Inc. Use of a bone morphogenetic protein in synergistic combination with tgf--g(b) for bone repair
EP0575555B1 (en) * 1991-03-11 2001-07-18 Curis, Inc. Protein-induced morphogenesis
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
WO1992020793A1 (en) 1991-05-10 1992-11-26 The Salk Institute For Biological Studies CLONING AND RECOMBINANT PRODUCTION OF RECEPTOR(S) OF THE ACTIVIN/TGF-β SUPERFAMILY
AU662155B2 (en) 1991-05-10 1995-08-24 Celtrix Pharmaceuticals, Inc. Targeted delivery of bone growth factors
JP3351525B2 (ja) 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
DK0592562T3 (da) 1991-06-25 1999-08-30 Genetics Inst BMP-9-præparater
ATE308336T1 (de) 1991-08-30 2005-11-15 Curis Inc Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
EP0601106B2 (en) * 1991-08-30 2003-11-05 Curis, Inc. Morphogen-induced modulation of inflammatory response
AU674500B2 (en) 1991-11-04 1997-01-02 Genetics Institute, Llc Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
US5733871A (en) * 1991-11-08 1998-03-31 The General Hospital Corporation Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
DE69228949T2 (de) * 1991-11-22 1999-09-16 Auckland Uniservices Ltd., Auckland Tgf-beta zur verbesserung der regeneration von neuronalem gewebe
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
AU681594B2 (en) 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
CA2169191C (en) 1993-08-26 2008-01-15 Elizabeth A. Wang Neural regeneration using human bone morphogenetic proteins
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000508561A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000500026A5 (enExample)
JP2001502086A5 (enExample)
JP2000502472A5 (enExample)
JP2000507939A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000517074A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000509412A5 (enExample)
JP2000501744A5 (enExample)
JP2000502316A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)
JP2000502479A5 (enExample)
JP2000501918A5 (enExample)
JP2000501513A5 (enExample)